Fortis Healthcare-owned Agilus Diagnostics Limited has filed its Draught Red Herring Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI) in order to raise funds in the primary markets.
The offering for sale (OFS) consists of up to 14,233,964 equity shares in which International Finance Corporation l, NYLIM Jacob Ballas India Fund III LLC, and Resurgence PE Investments will seek to sell their holdings.
International Finance Corporation will sell up to 29.85 lakh shares under the OFS, while NYLIM Jacob and Resurgence will offer up to 74.62 lakh and 37.86 lakh equity shares, respectively.
The face value of the shares is Rs 10 each.
The company, which is marketed by Fortis Healthcare, claims to be India's largest diagnostics service provider in terms of laboratory count and second largest in terms of revenue from operations as of March 31, 2023 for the fiscal year in question.
According to a company release, the shares will be listed on the BSE and NSE.
The issue's book-running lead managers are
ICICI Securities Limited, Axis Capital Limited, and Citigroup Global Markets India Private Limited, and the registrar is KFin Technologies Limited.
According to the DRHP, the company's net value was Rs 1,803.76 crore at the end of FY23, up from Rs 1,724.34 crore in FY22 and Rs 1,169.57 crore in FY21.
The company provides diagnostic testing services, wellness and preventive care packages, hospital laboratory management services, and clinical research trial testing services, as per a statement from the company.
